Research
Hormonal
Higher abundance of Dysosmobacter welbionis in the human gut is negatively correlated with Body Mass Index (BMI), fasting glucose, and glycated hemoglobin (HbA1c) in obese individuals with metabolic syndrome.
In humans with obesity and metabolic syndrome, higher levels of Dysosmobacter welbionis in the gut are associated with lower BMI, better blood sugar control, and lower HbA1c. This suggests that maintaining or increasing this bacterium may be beneficial for metabolic health.
LimitedSupportsMEDIUM confidence
in obese humans with a metabolic syndrome, the abundance of Dysosmobacter genus correlates negatively with body mass index, fasting glucose and glycated haemoglobin.
Why this rating
Observational data from human cohorts; correlation does not prove causation.
Source
<i>Dysosmobacter welbionis</i> is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice
Tiphaine Le Roy et al. · Gut · 2021
DOI 10.1136/gutjnl-2020-323778
mechanism_only · n=11984Cited 220×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →